NCT06039891View on ClinicalTrials.gov

Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2027

Conditions
Cervical Cancer
Interventions
DRUG

Nimotuzumab、Tislelizumab

Subjects will receive Nimotuzumab 400 mg/time, intravenous injection, qw; Tislelizumab 200 mg/time, q3w until disease progression, intolerable toxicity, or 24 months of medication

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT06039891 - Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer | Biotech Hunter | Biotech Hunter